Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Vivoryon Therapeutics AG    VVY   DE0007921835

VIVORYON THERAPEUTICS AG

(VVY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
11/24/2020 11/25/2020 11/26/2020 11/27/2020 11/30/2020 Date
6.38(c) 6.8(c) 6.78(c) 6.82(c) 6.73(c) Last
222 050 406 311 182 711 284 799 126 426 Volume
-2.74% +6.58% -0.29% +0.59% -1.32% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -11,6 M -13,8 M -13,8 M
Net cash position 2020 14,9 M 17,8 M 17,8 M
P/E ratio 2020 -11,6x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -20,8 M -24,8 M -24,8 M
Net cash position 2021 4,46 M 5,31 M 5,31 M
P/E ratio 2021 -6,47x
Yield 2021 -
Capitalization 134 M 161 M 160 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 17
Free-Float 61,0%
More Financials
Company
Vivoryon Therapeutics AG (formerly Probiodrug) specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2018, the group has a portfolio of 2 products in clinical development phase (PBD-C06 and PQ912) and a product in the preclinical development phase. 
More about the company
All news about VIVORYON THERAPEUTICS AG
04:29aVIVORYON THERAPEUTICS : Announces Conversion into Vivoryon Therapeutics N.V.
PU
01:01aVIVORYON THERAPEUTICS N.V. : Vivoryon Therapeutics AG Announces Conversion into ..
EQ
11/26VIVORYON THERAPEUTICS : Interim Management Report Q3 2020 (english)
PU
11/26VIVORYON THERAPEUTICS AG : Vivoryon Therapeutics Reports Third Quarter 2020
EQ
11/19VIVORYON THERAPEUTICS : to Publish its Third Quarter 2020 Business Update on Nov..
PU
11/19VIVORYON THERAPEUTICS AG : Vivoryon Therapeutics AG to Publish its Third Quarter..
EQ
10/01VIVORYON THERAPEUTICS AG : Ordinary General Meeting of Shareholders of Vivoryon ..
EQ
09/30VIVORYON THERAPEUTICS AG : Proxy Statments
CO
09/03VIVORYON THERAPEUTICS AG : Vivoryon Therapeutics Announces Notice of its Ordinar..
EQ
08/27VIVORYON THERAPEUTICS : plans conversion into Naamloze Vennootschap (N.V.) under..
PU
08/27VIVORYON THERAPEUTICS AG : Vivoryon Therapeutics AG plans conversion into Naamlo..
EQ
08/27VIVORYON THERAPEUTICS : Half Year 2020 Results Webcast and Conference Call Prese..
PU
08/27VIVORYON THERAPEUTICS : Interim Financial Statements 30 June 2020 (HGB) (english..
PU
08/27VIVORYON THERAPEUTICS AG : Vivoryon Therapeutics AG Reports Financial Results fo..
EQ
08/20VIVORYON THERAPEUTICS AG : Preliminary announcement of the publication of financ..
EQ
More news
News in other languages on VIVORYON THERAPEUTICS AG
11/26VIVORYON THERAPEUTICS : Interim Management Report Q3 2020 (deutsch)
08/20VIVORYON THERAPEUTICS AG : Vorabbekanntmachung über die Veröffentlichung von Fin..
03/19VIVORYON THERAPEUTICS AG : Vorabbekanntmachung über die Veröffentlichung von Fin..
01/14VIVORYON THERAPEUTICS AG : une collaboration prometteuse
2019STOCK MARKET PARIS : Happy End à tous les étages ?
More news
Chart VIVORYON THERAPEUTICS AG
Duration : Period :
Vivoryon Therapeutics AG Technical Analysis Chart | VVY | DE0007921835 | MarketScreener
Technical analysis trends VIVORYON THERAPEUTICS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 17,00 €
Last Close Price 6,73 €
Spread / Highest target 271%
Spread / Average Target 153%
Spread / Lowest Target 33,7%
EPS Revisions
Managers
NameTitle
Ulrich Dauer Chief Executive & Financial Officer
Frank T. Weber Chief Medical Officer
Jörg Neermann Independent Member-Supervisory Board
Dinnies Johannes von der Osten Vice Chairman-Supervisory Board
Charlotte Lohmann Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
VIVORYON THERAPEUTICS AG25.37%163
MODERNA, INC.549.44%50 267
LONZA GROUP AG56.23%45 319
CELLTRION, INC.82.04%40 460
IQVIA HOLDINGS INC.9.26%32 365
SEAGEN INC.48.01%30 493